LUNAPHORE/VISIOPHARM
4.5.2022 17:02:11 CEST | Business Wire | Press release
Lunaphore , a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Visiopharm , a company developing A.I.-driven precision pathology software, today announced a new partnership that will unite staining and imaging with A.I. analysis capabilities. Under the partnership, the companies will co-market a complete end-to-end solution that offers hyperplex immunofluorescence staining, image acquisition, and subsequent analysis with deep learning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005730/en/
The combined offering will include Lunaphore’s COMET™ , which can perform automated, hyperplex immunofluorescence staining and imaging, and Visiopharm’s Oncotopix® Discovery , an easy-to-use deep learning solution for tissue-based cancer research. COMET™ and Oncotopix® Discovery are compatible natively, and the combined offering provides an all-encompassing, interoperable spatial biology and data analysis solution for researchers.
Visiopharm is a world leader in A.I.-driven precision pathology software with over two decades experience pioneering innovation in digital pathology and partnering with the most recognized names in tissue-based disease research. With the launch of Oncotopix® Discovery, the most robust version of their respected research image analysis software platform to date, Visiopharm brings the power of deep learning to all. Oncotopix® Discovery allows any scientist, not just image analysis experts, to use their understanding of tissue morphology to train an A.I. deep learning APP to get accurate and reproducible data. The software also features the Multiplex Phenotyping module, an essential tool for investigating the tumor microenvironment revealed by staining platforms such as Lunaphore’s COMET™.
“The technology for staining and imaging multiplexed images is improving rapidly. However, the challenge is how to make sense of what is there,” says James Mansfield, Senior Vice President, Research Business Development at Visiopharm. “How do we interpret highplex staining in a way that not only reveals meaningful insights but does so accurately and reproducibly? That has been our focus from the beginning in developing our Multiplex Phenotyping module. We give researchers a beginning-to-end solution to create a cell phenotype map of the tissue microenvironment and then a set of helpful visualization tools like t-SNE plots and matrixes to verify and interpret the data.”
“That is where we see a powerful synergy between Visiopharm and Lunaphore,” Mansfield continued. “We are both interested in arming researchers with tools to conduct spatial biology analysis that deliver reproducible results. This is essential for true advancement to be made in both basic and especially translational studies.”
With superior tissue profiling capabilities, the COMET™ platform allows a multiplex analysis of up to 40 separate spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications across immuno-oncology, neuroscience, and infectious diseases.
“Our partnership with Visiopharm allows us to create a unified technology solution that can enhance our understanding of cancer pathology,” said Déborah Heintze, Chief Marketing Officer of Lunaphore. “By combining our leading spatial biology platform with Visiopharm’s deep learning capabilities, this collaboration can make it easier for laboratories to adopt and integrate spatial biology solutions for their research.”
To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
To learn more about Oncotopix Discovery, please visit: https://visiopharm.com/oncotopix-discovery/
To learn more about Visiopharm, please visit: https://visiopharm.com/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com .
About Visiopharm
Visiopharm® is a world leader in AI-driven precision pathology software. Their pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.
Visiopharm was founded in 2002 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, Netherlands and United States.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005730/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logistics Reply Expands Robot-Assisted Fulfilment at The Quality Group19.11.2026 10:00:00 CET | Press release
Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the site manage highly dynamic order volumes and process up to 100,000 orders per day across its 50,000-square-metre facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119787784/en/ Logistics Reply, the Reply Group company specialised in software solutions for supply chain execution and warehouse management, has deepened its collaboration with The Quality Group (TQG) by implementing an agile intralogistics system for the company’s new fulfilment centre in Elsdorf, near Bremen. The project combines autonomous robotics with human expertise to help the sit
Twilio Powers Chelsea FC to Cut Campaign Launch Times from 48 Hours to Under 15 Minutes19.11.2026 10:00:00 CET | Press release
Twilio Segment gives Chelsea a more connected view of its global fanbase for real-time responses to personal interests and match moments on the pitch Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its SIGNAL World Tour London, by unveiling that Chelsea Football Club has slashed campaign launch times from 48 hours to under 15 minutes with Twilio Segment. Building a Single View of the Global Fan Chelsea’s global fans interact with the Club across matchdays, ticketing, its mobile app, ecommerce and other digital experiences. Historically, these interactions sat across siloed systems, creating duplicate customer records for a single fan. By consolidating its data, Chelsea removed over 460,000 duplicate records. With this cleaner and unified fan database, campaign launch time has been reduced from 48+ hours to under 15 minutes. Beyond the Pitch: Elevating the Fan Experience Chelsea is now able to send its fans highly relevant messages tailored to t
EDAN Presents Integrated Medical Innovations at MEDICA 2026, Strengthening Global Healthcare Connections19.11.2026 09:49:00 CET | Press release
Edan Instruments, Inc. (300206. SZ), a global provider of medical devices and healthcare solutions, is presenting its latest innovations at MEDICA 2026, taking place November 16–19 in Düsseldorf. The event provides an important platform for industry exchange and an opportunity for EDAN to engage with European partners on evolving healthcare needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118813326/en/ “Germany and Europe are important partners in the global healthcare industry. As China’s medical technology sector expands internationally, closer collaboration with European healthcare professionals and industry partners can create opportunities for shared progress,” said Alex You, Senior Director of Marketing, Customer Service, Global Connectivity & Integration at EDAN. “By understanding local clinical needs and translating them into accessible, reliable solutions, we can contribute to more effective healthcare. MEDI
Ant International's Alipay+ to Connect over 50 Global E-Wallets with Pix of Brazil19.11.2026 09:43:00 CET | Press release
Expanding Alipay+'s national QR scheme connections to 16, spanning Asia, the Middle East and Latin AmericaEnabling international travellers to pay with home wallets at Pix merchants across Brazil, supporting local businesses and inbound tourism Ant International today announced that Alipay+, its global wallet gateway that links over 50 global digital wallets and banking apps, is connected to Pix, Brazil's national instant payment system, expanding cross-border digital payment access for international travellers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119229229/en/ Ant International's global wallet gateway Alipay+ is connecting over 50 e-wallets and banking apps to Pix Powered by Ant International’s AI-native payment and risk management capabilities, the service allows international travellers using their familiar payment apps to scan Pix QR codes at shops, restaurants, and attractions nationwide, without downloadi
Summit Risk Partners Limited Opens for Business as a Registered Lloyd’s Broker Through its Regulated Subsidiaries19.11.2026 09:00:00 CET | Press release
New K2 division launches a modern, data-driven broking house dedicated to the delegated authority sector. Summit Risk Partners Limited (SRP), a newly launched division of K2 Insurance Services, announced today it is officially open for business as a registered Lloyd’s broker. Built specifically for the future of delegated authority, SRP aims to elevate service provision and set a new standard for outcomes across delegated and programme business in the Lloyd’s and London markets. Co-founded by James Baird, CEO, and Jamie Beckett, Managing Director, the specialist broking house operates free from legacy systems and mindsets. SRP combines deep industry expertise with modern technology, actionable insight, and a relentless focus on client success for coverholders, MGAs, underwriting businesses and capacity providers. Key Operational Highlights: Market Status: Registered Lloyd’s broker trading under the pseudonym SUM (Broker Number 2336), sponsored by three leading Lloyd’s Managing Agents.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
